First author Hamilton Oh, now at Icahn School of Medicine at Mt. Sinai, New York, and colleagues identified these potential markers during a proteomics analysis of CSF from 3,397 participants in six ...

Like lecanemab before it, donanemab’s path to market has been slow and rocky. In the U.S., the antibody received Food and Drug Administration approval about nine months ago, but only a few hundred ...

The first evidence that removing amyloid plaques may delay Alzheimer’s symptoms has now been published. In The Lancet Neurology on March 19, scientists led by Randall Bateman at Washington University ...

Do you know a conference you think we should list? Let us know by sending us an email with the details to [email protected].

I am consultant for Janssen pharmaceutica, Remynd NV, Eisai and other companies ...

12 June 2025 DOWNLOAD TO YOUR CALENDAR Online Meeting View Conference Website ...